No Data
No Data
CervoMed Announces Executive Appointments and Changes
Express News | Watching CervoMed; Shares Spike Higher, Traders Circulate Newsletter Mention
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $15
CervoMed's Promising Data and Phase 3 Prospects Boost Buy Rating
CervoMed Reports Positive Phase 2b Trial Results
Top 10 Russell 2000 Weekly Gainers and Losers as Wall Street Crashes
Sewerman : when?